Table 1.
Some of the main mutations found in intrahepatic cholangiocarcinoma and their corresponding target therapy options.
| Mutation | Frequency (%) * | Potential Target-Therapies |
|---|---|---|
| TP53 | 18–43 | Idasanutlin, Alrizomadlin, Eprenetapopt, SAR405838, Milademetan |
| IDH1 | 22 | Ivosidenib |
| IDH2 | 5 | Enasidenib |
| KRAS | 10–18 | Sotorasib, Adagrasib, Selumetinib, Trametinib |
| ARID1A | 19–22 | Olaparib, Niraparib, Rucaparib, Veliparib, Ceralasertib, Berzosertib |
| BAP1 | 9–19 | Olaparib |
| BRAF | 7 | Dabrafenib, Trametinib, Vemurafenib, Encorafenib |
| FGFR2 | 5 | Derazantinib, Infigratinib, Pemigatinib, Futibatinib, Ponatinib, Erdafitinib, Debio 1347 |
| Her2 | 1 | Trastuzumab, Pertuzumab, Lapatinib, Tucatinib, Neratinib, Varlitinib, Taselisib |
* According to Guo et al. and Weinberg et al. [16,19]. TP53: tumor protein p53; IDH1: isocitrate dehydrogenase 1; IDH2: isocitrate dehydrogenase 2; KRAS: Kirsten rat sarcoma virus; ARID1A: AT-rich interactive domain-containing protein 1A; BAP1: BRCA1-associated protein-1; BRAF: V-raf murine sarcoma viral oncogene homolog B; FGFR2: fibroblast growth factor receptor 2; Her2: human epidermal growth factor receptor 2.